Results 201 to 210 of about 4,927 (252)
Some of the next articles are maybe not open access.
Photochemistry and Phototoxicity of Fluocinolone 16,17-Acetonide¶
Photochemistry and Photobiology, 2004ABSTRACTFluocinolone 16,17‐acetonide is a corticosteroid used topically to treat various inflammatory skin diseases. Its photoreactivity was studied under UV‐A and UV‐B light in aqueous buffer in the presence of oxygen. This drug is photolabile under UV‐B light and, to a lesser extent, under UV‐A light, which is absorbed far less.
MIOLO, GIORGIA +5 more
openaire +3 more sources
Treatment of radiation-induced maculopathy with fluocinolone acetonide
Graefe's Archive for Clinical and Experimental Ophthalmology, 2020Chronic macular oedema is a well-known presentation of radiation-induced maculopathy (RM) following external beam photon therapy, plaque radiotherapy and proton beam radiotherapy for choroidal tumours. Current therapies vary in respect of efficacy and clinical benefit. The potential of fluocinolone acetonide (FAc) slow-release implants is unknown.
Lena Zimmermann +4 more
openaire +3 more sources
Solid-state investigation of fluocinolone acetonide
Journal of Pharmaceutical and Biomedical Analysis, 1997Three crystalline modifications of fluocinolone acetonide, A, B and C, were characterized by means of FTIR, DSC, TG-FTIR, MICRO-FTIR and X-ray diffractometry. They were easily differentiated by their IR absorption bands in the 3600-3400 cm-1 range. The thermal behavior was also elucidated using combined techniques; thermomicroscopy and thermogravimetry
Marina Cotta Ramusino +2 more
openaire +3 more sources
Fluocinolone acetonide for the treatment of diabetic macular edema
Expert Opinion on Pharmacotherapy, 2017Fluocinolone acetonide intravitreal implant is a non-erodible implant approved for the treatment of diabetic macular edema (DME) insufficiently responsive to available therapies. Areas covered: The injectable intravitreal implant releases fluocinolone acetonide at an average rate of 0.2 µg/day for at least 36 months.
VERITTI, Daniele +4 more
openaire +3 more sources
Archives of Dermatology, 1963
Regrowth of hair in patients with alopecia areata and alopecia totalis has been demonstrated following intralesional injection or systemic administration with corticosteroid drugs.1-4Intralesional injection is painful and may be followed by atrophy, and systemic administration is often accompanied by the undesirable effects of these drugs.
Kenneth A. Gill, Donald L. Baxter
openaire +3 more sources
Regrowth of hair in patients with alopecia areata and alopecia totalis has been demonstrated following intralesional injection or systemic administration with corticosteroid drugs.1-4Intralesional injection is painful and may be followed by atrophy, and systemic administration is often accompanied by the undesirable effects of these drugs.
Kenneth A. Gill, Donald L. Baxter
openaire +3 more sources
Fluocinolone Acetonide in Propylene Glycol
Archives of Dermatology, 1963Eighty patients with varying types of inflammatory dermatoses were treated with a liquid solution containing fluocinolone acetonide 0.01% dissolved in propylene glycol. * While the over-all results were not as good as those reported for the 0.025% vanishing cream preparation, it was particularly effective for some patients whose dermatoses involved the
openaire +3 more sources
ChemInform Abstract: PRODUCTION OF FLUOCINOLONE ACETONIDE
Chemischer Informationsdienst, 1979AbstractAusgehend vom 21‐Acetat des 6a‐Fluorpregnatrienoldions (I) erhält man die Titelverbindung (IV) über das Bromhydrin (II) und das Epoxid (III).
G. S. Grinenko +3 more
openaire +2 more sources
Fluocinolone Acetonide Implantable Device for Diabetic Retinopathy
Current Pharmaceutical Biotechnology, 2011Diabetic retinopathy remains a major worldwide cause of preventable visual loss. Although photocoagulation and improved metabolic control are effective for patients with diabetic macular edema and proliferative diabetic retinopathy, some patients continue to lose vision despite treatment.
Harry W. Flynn, Stephen G. Schwartz
openaire +3 more sources
Management of Sympathetic Ophthalmia with the Fluocinolone Acetonide Implant
Ophthalmology, 2009We examined whether implantation of the fluocinolone acetonide (Retisert) implant achieved control of inflammation and a reduced need for oral corticosteroids or immunosuppressives in patients with sympathetic ophthalmia (SO).Retrospective, noncomparative case series.Eight patients with active SO.The results of fluocinolone acetonide implantation in 8 ...
David H. Fischer +5 more
openaire +3 more sources
Response of Psoriatic Lesions to Topical Fluocinolone Acetonide
Archives of Dermatology, 1963This study consisted of an additional 6-10 month follow-up of 214 patients (previously reported on) 1 with psoriasis treated with fluocinolone acetonide cream and occlusive dressings. All but one of 102 patients with intertriginous involvement with psoriasis responded well to the topical use of fluocinolone acetonide without an occlusive dressing ...
Harvey B. Ansell +2 more
openaire +3 more sources